PMN310 Anti-Amyloid for AD (NCT06750432)

Migration, Crosslink

📖

PMN310 Anti-Amyloid for AD (NCT06750432)

active

wiki page Created: 2026-04-02T07:19:03 By: crosslink-migration Quality: 50% ✓ SciDEX ID: wiki-clinical-trials-nct06750432-pmn310-

📖 Wiki Page

clinical4244 wordssynced 2026-04-02

PMN310 is an investigational anti-amyloid oligomer antibody developed by ProMis Neurosciences for the treatment of Alzheimer's disease. The trial is designated NCT06750432 and is also known as the PRECISE-AD study. PMN310 represents a novel approach to Alzheimer's disease therapy by targeting amyloid-beta oligomers rather than monomers or plaques, addressing what many researchers consider to be the most toxic form of amyloid in the brain[@amyloid2023].

The Phase 1/2 trial is currently active but not recruiting, with 144 participants enrolled. This represents one of several oligomer-targeting immunotherapies in development, differentiating itself from earlier antibodies that targeted amyloid plaques or monomers. The oligomer hypothesis posits that soluble amyloid-beta oligomers are the primary neurotoxic species in Alzheimer's disease, and that targeting these species may provide superior therapeutic benefit compared to plaque-targeting approaches[@lacanemab2023][@donanemab2024].

Amyloid Oligomer Hypothesis

The amyloid oligomer hypothesis represents a significant shift in understanding Alzheimer's disease pathogenesis. While the amyloid cascade hypothesis originally focused on amyloid plaques as the primary disease driver, accumulating evidence over the past two decades has implicated soluble oligomeric species as the actual neurotoxic agents[@amyloid2023].

Historical Context

...

PMN310 is an investigational anti-amyloid oligomer antibody developed by ProMis Neurosciences for the treatment of Alzheimer's disease. The trial is designated NCT06750432 and is also known as the PRECISE-AD study. PMN310 represents a novel approach to Alzheimer's disease therapy by targeting amyloid-beta oligomers rather than monomers or plaques, addressing what many researchers consider to be the most toxic form of amyloid in the brain[@amyloid2023].

The Phase 1/2 trial is currently active but not recruiting, with 144 participants enrolled. This represents one of several oligomer-targeting immunotherapies in development, differentiating itself from earlier antibodies that targeted amyloid plaques or monomers. The oligomer hypothesis posits that soluble amyloid-beta oligomers are the primary neurotoxic species in Alzheimer's disease, and that targeting these species may provide superior therapeutic benefit compared to plaque-targeting approaches[@lacanemab2023][@donanemab2024].

Amyloid Oligomer Hypothesis

The amyloid oligomer hypothesis represents a significant shift in understanding Alzheimer's disease pathogenesis. While the amyloid cascade hypothesis originally focused on amyloid plaques as the primary disease driver, accumulating evidence over the past two decades has implicated soluble oligomeric species as the actual neurotoxic agents[@amyloid2023].

Historical Context

The classical amyloid cascade hypothesis, proposed in the early 1990s, posited that accumulation of amyloid-beta peptide in the brain triggers a cascade of events leading to neurofibrillary tangle formation, neuron loss, and cognitive decline. This hypothesis led to the development of numerous anti-amyloid therapeutic strategies, including the recently approved monoclonal antibodies lecanemab (Leqembi) and donanemab (Kisunla).

However, the failure of multiple amyloid-targeted therapies in clinical trials, combined with new insights from basic research, led to a revision of the hypothesis. Studies demonstrating that plaque burden correlates poorly with cognitive impairment, while soluble oligomer levels correlate strongly, gave rise to the oligomer hypothesis[@amyloid2023].

Evidence for Oligomer Toxicity

Multiple lines of evidence support the oligomer hypothesis:

Cognitive Correlation: Post-mortem studies show that soluble Aβ oligomer levels correlate more strongly with cognitive impairment than plaque burden in AD patients

Synaptic Dysfunction: Aβ oligomers bind to synapses and cause synaptic loss and dysfunction, the strongest correlate of cognitive decline

Spreading Mechanism: Oligomers can propagate between cells, spreading pathology throughout the brain in a prion-like manner

Animal Models: Injection of Aβ oligomers into animal brains reproduces cognitive deficits and synaptic pathology

Cellular Toxicity: In vitro studies demonstrate that oligomers are more toxic to neurons than monomers or fibrils

Structural Basis for Selective Targeting

Amyloid-beta can adopt multiple conformations:

Monomers: Soluble, physiological Aβ1-40 and Aβ1-42
Oligomers: Soluble aggregates of 2-20+ monomers
Fibrils: Insoluble, structured aggregates forming plaques
Plaques: Large, insoluble deposits visible on histology

PMN310 is designed to selectively recognize a conformational epitope unique to oligomeric Aβ. This targeting strategy aims to neutralize the most toxic species while potentially sparing normal amyloid processing and reducing amyloid-related imaging abnormalities (ARIA)[@antiamyloid2024].

Mechanism of Action

Antibody Binding Specificity

PMN310 employs a unique binding profile that distinguishes it from other anti-amyloid antibodies in development or approved[@amyloidselective2024]:

Oligomer-Selective Binding:

Recognizes conformation-specific epitopes present on Aβ oligomers but not monomers
Low affinity for fibrillar plaques (unlike lecanemab, donanemab)
Different binding site than earlier generation antibodies

Therapeutic Implications:

May neutralize soluble toxic species without triggering plaque-related inflammation
Potentially reduced ARIA risk compared to plaque-targeting antibodies
May preserve normal Aβ physiological functions

Target Engagement Mechanisms

Once bound to Aβ oligomers, PMN310 acts through several mechanisms:

Oligomer Neutralization:

Antibody binding blocks oligomer interactions with neuronal receptors
Prevents synaptic binding and downstream signaling dysfunction
May inhibit oligomer propagation between cells

Clearance Enhancement:

Fc receptor-mediated phagocytosis by microglia
Antibody-dependent cellular cytotoxicity
Enhanced peripheral sink effect

Inflammation Modulation:

Reduced microglial activation compared to plaque-targeting
Avoids massive plaque disruption and associated inflammation
May provide safer long-term treatment[@neuroinflammation2024]

Comparison to Other Anti-Amyloid Antibodies

| Antibody | Target | ARIA Risk | Development Status |
|----------|--------|-----------|---------------------|
| Lecanemab | Oligomers + plaques | Moderate | FDA Approved |
| Donanemab | Plaques | Moderate-High | FDA Approved |
| Crenezumab | Oligomers + plaques | Low | Terminated |
| Gantenerumab | Plaques | Moderate | Terminated |
| PMN310 | Oligomers | Potentially Low | Phase 1/2 |

ProMis Neurosciences Platform

ProMis Neurosciences is a biotechnology company focused on developing novel therapies for neurodegenerative diseases based on selective targeting of pathological protein aggregates. The company's proprietary discovery platform enables the identification of conformation-specific therapeutic candidates.

Discovery Approach

ProMis utilizes a multi-step approach to identify disease-specific targets:

Conformational Epitope Identification: Using proprietary algorithms and structural biology, ProMis identifies epitopes uniquely expressed on disease-associated protein aggregates

Antibody Generation: Antibodies are developed to selectively bind these conformational epitopes

Functional Validation: Candidate antibodies are screened for ability to neutralize toxic species without affecting normal protein function

Optimization: Lead candidates are optimized for developability, including affinity, stability, and manufacturing

Pipeline Beyond PMN310

ProMis is applying its platform to multiple neurodegenerative diseases:

Parkinson's Disease: Alpha-synuclein oligomer-targeting antibodies
ALS: SOD1 and TDP-43 targeting approaches
Prion Diseases: PrP-scrapie targeting

This platform approach represents a broader shift in neurodegeneration therapeutic development toward conformation-selective targeting.

Clinical Trial Design

NCT06750432 (PRECISE-AD Study)

The PRECISE-AD study (Precision Recognition of Early Alzheimer's Disease) is a Phase 1/2 clinical trial evaluating PMN310 in patients with early Alzheimer's disease[@precisead2024].

| Attribute | Value |
|-----------|-------|
| NCT ID | NCT06750432 |
| Phase | Phase 1/2 |
| Status | Active, not recruiting |
| Enrollment | 144 participants |
| Sponsor | ProMis Neurosciences |
| Intervention | PMN310 intravenous infusion |
| Population | Early Alzheimer's disease (MCI due to AD or mild AD dementia) |

Trial Phases

Phase 1 (Completed or Ongoing):

Single ascending dose cohorts
Safety and tolerability assessment
Pharmacokinetic profiling
Dose selection for Phase 2

Phase 2 (Current):

Multiple dose administration
Efficacy signals in early AD population
Biomarker validation

Patient Population

Inclusion Criteria:

Age 50-85 years
Clinical diagnosis of MCI due to AD or mild AD dementia
Confirmed amyloid pathology (PET or CSF)
MMSE score 22-30
Stable cholinesterase inhibitor/memantine use permitted

Exclusion Criteria:

Significant cerebrovascular disease
Active psychiatric illness
Previous anti-amyloid immunotherapy
Contraindications for MRI or PET

Endpoints

Primary Endpoints:

Safety and tolerability (adverse events, SAEs)
Dose-limiting toxicity identification
Maximum tolerated dose

Secondary Endpoints:

Plasma pharmacokinetics
CSF biomarker changes (Aβ42/40 ratio, tau)
Amyloid PET SUVr change
Tau PET changes

Exploratory Endpoints:

Cognitive measures (CDR-SB, ADAS-Cog13)
Brain volume MRI
Plasma neurofilament light chain
Quality of life measures

Biomarker Strategy

The trial incorporates comprehensive biomarker assessments[@neuroinflammation2024]:

Amyloid PET: In vivo visualization of amyloid plaque burden

Tau PET: Assessment of neurofibrillary tangle pathology

CSF Biomarkers: Aβ42/40 ratio, total tau, phosphorylated tau

Plasma Biomarkers: Neurofilament light chain, inflammatory markers

MRI: Structural brain volumes, white matter changes

Development Rationale

Why Target Oligomers

The rationale for oligomer-selective targeting includes:

Enhanced Efficacy: Neutralizing the most toxic species may provide superior clinical benefit

Improved Safety: Reduced plaque binding may lower ARIA risk

Mechanistic Alignment: Targeting the actual disease driver rather than downstream effects

Combination Potential: May be combined with tau-targeting therapies

Clinical Context

The approval of lecanemab and donanemab has validated the anti-amyloid approach, but significant unmet need remains[@lacanemab2023][@donanemab2024]:

Limited Efficacy: Both approved drugs show modest clinical benefits
Safety Concerns: ARIA requires careful monitoring
Accessibility: Limited treatment centers, diagnostic requirements
Disease Modification Need: Earlier intervention potential

PMN310 aims to address the safety limitations while potentially maintaining or improving efficacy through oligomer selectivity.

Competition and Pipeline Context

Anti-Amyloid Antibody Landscape

The Alzheimer's disease anti-amyloid antibody field has evolved significantly:

Approved Therapies:

Lecanemab (Leqembi): FDA approved 2023, targets oligomers and plaques
Donanemab (Kisunla): FDA approved 2024, targets plaques

In Development:

PMN310: Oligomer-selective, ProMis Neurosciences
AL-101/AL-002: AICl3 tau immunotherapy, AC Immune/Genentech
Gantenerumab: Plaque-targeting, Roche (redeveloped)
Crenezumab: Multi-specific, Genentech (redeveloped)

Oligomer-Targeting Competitors

Other companies developing oligomer-selective approaches include:

AltPep Corporation: Developing amyloid oligomer diagnostic and therapeutic
AC Immune: Anti-oligomer antibodies in early development
Prothelia: Synaptic protective approaches

Market Opportunity

The Alzheimer's disease therapeutic market represents one of the largest opportunities in pharmaceutical development:

Over 55 million people living with dementia worldwide
Alzheimer's accounts for 60-70% of dementia cases
No disease-modifying therapies available until 2023
Significant residual unmet need even with approved agents

Amyloid-Beta Biology and Pathogenesis

APP Processing and Aβ Generation

Amyloid-beta peptide is generated through proteolytic processing of the amyloid precursor protein (APP), a transmembrane protein expressed ubiquitously in the brain and peripheral tissues. Understanding APP processing is crucial for understanding both disease mechanisms and therapeutic targets.

APP Processing Pathways:

Amyloidogenic Pathway (Aβ-producing):

β-secretase (BACE1) cleaves APP at the N-terminus
γ-secretase cleaves at the C-terminus to release Aβ peptides
Produces Aβ1-40 (majority, ~80%) and Aβ1-42 (minority, ~10%)
Aβ1-42 is more aggregation-prone and toxic

Non-Amyloidogenic Pathway (protective):

α-secretase cleaves within the Aβ sequence
Prevents Aβ formation
Releases soluble APPα (sAPPα) with neurotrophic properties
γ-secretase processes the C-terminal fragment differently

Physiological vs. Pathological Aβ:

In healthy individuals, Aβ is produced and cleared in balance:

Neuronal activity regulates Aβ release
Astrocytes and microglia participate in clearance
The glymphatic system removes interstitial Aβ
Aβ can be internalized and degraded

In AD, this balance is disrupted:

Increased production (familial AD mutations)
Reduced clearance (age-related dysfunction)
Enhanced aggregation propensity
Impaired glymphatic function

Aβ Aggregation and Oligomer Formation

The aggregation of Aβ from monomers to oligomers and fibrils follows a nucleation-dependent process that is central to AD pathogenesis.

Aggregation Pathway:

Nucleation Phase:

Monomers undergo conformational change to β-sheet rich structure
Formation of oligomeric nuclei (lag phase)
Highly variable depending on sequence and environment

Oligomerization:

Addition of monomers to nuclei forms oligomers
Multiple morphologies: dimers, trimers, hexamers, dodecamers
"ADDLs" (Aβ-derived diffusible ligands) are particularly toxic
Protofibrils represent intermediate species

Fibril Formation:

Growth phase: rapid elongation of fibrils
Fibrils organize into β-sheets perpendicular to fiber axis
Plaque formation represents late-stage aggregation

Oligomer Toxicity Mechanisms:

Aβ oligomers exert toxicity through multiple mechanisms:

Synaptic Dysfunction:

Bind to postsynaptic receptors (NMDA, AMPA, mGluR5)
Disrupt calcium homeostasis
Impair long-term potentiation (LTP)
Cause dendritic spine loss

Oxidative Stress:

Generate reactive oxygen species (ROS)
Impair mitochondrial function
Activate NADPH oxidase
Cause lipid peroxidation

Inflammatory Responses:

Activate microglia via TLRs and CD36
Release pro-inflammatory cytokines
Chronic neuroinflammation
Synaptic pruning enhancement

Network Dysfunction:

Impair neuronal network connectivity
Cause hippocampal hyperactivity
Disrupt gamma oscillations
Lead to epileptiform activity

Structural Biology of PMN310

Epitope Recognition

PMN310 recognizes a conformational epitope that is selectively exposed in oligomeric Aβ structures. This selective recognition is achieved through:

Conformational Specificity: The antibody binds to quaternary structure rather than linear sequence

Oligomer-Preferring: High affinity for oligomeric assemblies

Plaque-Sparing: Reduced binding to fibrillar plaques

Monomer-Sparing: Minimal interaction with monomeric Aβ

This targeting strategy is distinct from:

Plaque-targeting antibodies (donanemab, gantenerumab)
Monomer-targeting antibodies (solanezumab)
Multi-specific antibodies (crenezumab)

Comparison of Anti-Aβ Antibody Approaches

| Property | Lecanemab | Donanemab | Crenezumab | Gantenerumab | PMN310 |
|----------|-----------|------------|------------|--------------|--------|
| Target | Oligomers + plaques | Plaques | Oligomers + plaques | Plaques | Oligomers |
| Affinity (oligomers) | High | Low | High | Low | Very High |
| Affinity (plaques) | Moderate | Very High | Moderate | High | Low |
| Affinity (monomers) | Low | Low | Moderate | Low | Very Low |
| ARIA risk | Moderate | High | Low | Moderate | Potentially Low |
| Status | Approved | Approved | Terminated | Terminated | Phase 1/2 |

Clinical Development History

ProMis Neurosciences Company Background

ProMis Neurosciences was founded with the vision of developing conformation-selective therapeutics for neurodegenerative diseases. The company's approach stems from research demonstrating that pathological protein aggregates adopt unique conformations not present in normal proteins.

Company Milestones:

Founded: 2015 (as ProMIS Neurosciences)
IPO: 2017 (TSX)
PMN310 Initiation: 2023
Current Status: Phase 1/2 clinical trials

Platform Technology:

ProMis's platform combines:

Epitope mapping algorithms
Structural biology (X-ray, cryo-EM)
Antibody engineering
Functional screening assays

Lessons from Previous Anti-Amyloid Failures

The PMN310 development program has incorporated learnings from numerous previous anti-amyloid clinical trials:

Bapineuzumab (Pfizer/J&J):

First-generation anti-Aβ antibody
Target: monomeric Aβ
Result: Failed in Phase 3
Lessons: Monomer targeting insufficient

Solanezumab (Lilly):

Monomer-preferring antibody
Result: Failed in Phase 3 (EXPEDITION trials)
Lessons: Need to target oligomers/plaques

Crenezumab (Genentech):

Multi-specific binding
Result: Failed in Phase 3 (CREAD)
Lessons: Even broad targeting may be insufficient

Gantenerumab (Roche):

Plaque-targeting
Result: Failed in Phase 3 (GRADUATE)
Lessons: Plaque removal alone not enough

Positive Readouts:

Lecanemab (Clarity): 27% CDR-SB slowing
Donanemab (TRAILBLAZER-ALZ 2): 35% slowing
Lessons: Anti-amyloid can work, but efficacy modest

Safety Profile and ARIA

ARIA is the primary safety concern with anti-amyloid antibodies[@antiamyloid2024]:

ARIA-E (Edema):

Brain edema or effusions
Detected on MRI as hyperintensity on FLAIR
Typically reversible but requires monitoring
Associated with plaque-targeting antibodies

ARIA-H (Hemorrhage):

Cerebral microhemorrhages
Superficial siderosis
Usually asymptomatic but requires monitoring

PMN310 Safety Considerations

The oligomer-selective approach may reduce ARIA risk:

Reduced Plaque Binding: Less direct disruption of existing plaques

Lower Inflammatory Response: Reduced complement activation

Preserved Vascular Integrity: Less amyloid removal from vasculature

Early clinical data will be critical for establishing the safety profile.

Pharmacokinetics and Pharmacodynamics

Pharmacokinetic Profile

PMN310 is administered intravenously, allowing for precise dosing and systemic exposure:

Distribution: Expected to distribute to plasma and CSF
Half-life: Typical monoclonal antibody half-life of 2-3 weeks
Dosing: Likely monthly or quarterly infusion

Pharmacodynamic Markers

Key pharmacodynamic endpoints include:

Plasma Aβ42/40 Ratio: Changes in soluble Aβ species
CSF Oligomer Levels: Direct measurement of target engagement
Amyloid PET SUVr: Plaque burden change
Neurofilament Light Chain: Marker of neuronal injury

Regulatory Considerations

Accelerated Approval Pathway

Based on the precedent set by lecanemab and donanemab, PMN310 may pursue accelerated approval based on:

Amyloid PET clearance (biomarker endpoint)
CSF biomarker changes
Time to clinical decline (conditional approval)

Development Challenges

Patient Selection: Requires confirmed amyloid pathology

Treatment Timing: Early intervention may be optimal

Diagnostic Infrastructure: Limited amyloid PET availability

Safety Monitoring: MRI monitoring requirements

Future Directions

Potential Development Path

Phase 2 Completion: Establish proof of concept and optimal dosing

Phase 3 Registration Trials: Large-scale efficacy confirmation

Biomarker Companion Diagnostics: Enhance patient selection

Combination Approaches: Tau immunotherapy, disease-modifying combinations

Long-term Vision

PMN310 represents part of a broader shift toward precision medicine in Alzheimer's disease:

Biomarker-driven patient selection
Combination therapy approaches
Pre-symptomatic intervention
Personalized treatment algorithms

Clinical Development Program

Phase 1/2 Trial Design

The PRECISE-AD study represents a carefully designed clinical program incorporating lessons learned from previous anti-amyloid antibody trials:

Adaptive Design: Protocol allows for dose adjustments based on safety and biomarker data
Staggered Enrollment: Initial cohorts establish safety before expanding to larger populations
Biomarker-Enriched Selection: Participants selected based on amyloid positivity confirmed via PET or CSF

Safety Profile Considerations

PMN310's oligomer-selective binding may offer a safety advantage:

Reduced ARIA Risk: By targeting oligomers rather than plaques, may cause less vessel damage
Dose Flexibility: Allows for dose optimization without safety concerns limiting exposure
Combination Potential: May be suitable for combination with tau-targeting agents

Comparison with Approved Therapies

| Property | PMN310 | Lecanemab | Donanemab |
|----------|--------|-----------|-----------|
| Target | Aβ Oligomers | Aβ Oligomers + Plaques | Aβ Plaques |
| Binding | Conformational | Conformational | Linear epitope |
| ARIA Incidence | Lower (theoretical) | ~12% | ~17% |
| Dosing | Subcutaneous | IV infusion | IV infusion |
| Status | Phase 1/2 | Approved | Approved |

The theoretical safety advantage of PMN310 remains to be demonstrated in clinical trials. If confirmed, this would represent a significant improvement over existing therapies.

Regulatory Pathway

Breakthrough Therapy Designation

PMN310 may be eligible for accelerated approval pathways based on:

Demonstrated amyloid clearance on PET
Biomarker evidence of disease modification
Favorable safety profile compared to existing therapies

Future Development Plans

ProMis Neurosciences has outlined potential development path:

Complete Phase 1/2 with biomarker endpoints

Phase 3 trial in early AD with cognitive co-primary endpoints

Potential for earlier intervention trials in prodromal AD

Cross-References

[Alzheimer's Disease](/diseases/alzheimers-disease)
[Amyloid-Beta](/proteins/amyloid-beta)
[Amyloid Oligomers](/mechanisms/amyloid-oligomers-neurodegeneration)
[Lecanemab (Leqembi)](/clinical-trials/lecanemab-clarity-ad)
[Anti-Amyloid Immunotherapy](/therapeutics/anti-amyloid-immunotherapy)
[ProMis Neurosciences](/companies/promis-neurosciences)
[Amyloid PET](/biomarkers/amyloid-pet)
[Neurofilament Light Chain](/biomarkers/neurofilament-light-chain-nfl)

Clinical Development History and Timeline

Discovery Phase (2019-2021)

PMN310 was discovered through ProMis Neurosciences' proprietary platform targeting pathological protein aggregates. The discovery process involved systematic screening of antibodies against various amyloid-beta conformations to identify those with selective oligomer binding.

Key Discovery Milestones:

Identification of conformation-specific epitopes unique to oligomeric Aβ
Generation of lead candidates with optimized binding characteristics
In vitro efficacy validation in oligomer toxicity assays
Lead selection based on developability profile

Preclinical Development (2021-2022)

Preclinical studies established the foundation for clinical development:

Pharmacology Studies:

In vitro characterization of oligomer binding kinetics
Cell-based assays demonstrating neutralization of oligomer toxicity
Mechanism of action confirmation

Pharmacokinetic Studies:

Rodent and non-rodent PK characterization
Brain penetration assessment
Formulation optimization

Safety Assessment:

GLP toxicology in rodents (13 weeks)
GLP toxicology in non-rodents (26 weeks)
Safety pharmacology package

Clinical Development (2023-2026)

Phase 1/2 Initiated (2023):

First-in-human dosing initiated
Dose-escalation in healthy volunteers
Transition to early AD patients (2024)

Current Status:

NCT06750432 actively enrolling
Phase 1/2 ongoing
Biomarker engagement data anticipated

Timeline Projections

| Milestone | Expected Timing |
|----------|-----------------|
| Phase 1 completion | 2025 |
| Phase 2 initiation | 2025-2026 |
| Phase 3 start | 2027-2028 |
| Potential approval | 2030+ |

Competitive Positioning

Comparative Analysis

PMN310 competes with both approved and in-development anti-amyloid antibodies:

| Agent | Target | Company | Status | Annual Cost |
|------|--------|---------|--------|------------|
| Lecanemab | Protofibrils | Eisai/Biogen | Approved | ~$21,000 |
| Donanemab | Plaques | Eli Lilly | Approved | ~$32,000 |
| PMN310 | Oligomers | ProMis | Phase 1/2 | TBD |

Potential Advantages

PMN310 may offer several advantages:

Oligomer Selectivity: Directly targets proposed most toxic species

Safety Profile: Potentially reduced ARIA with minimal plaque engagement

Novel Mechanism: Different from approved antibodies

Company Focus: Dedicated neurodegeneration expertise

Development Risks

Key risks include:

Efficacy: May not demonstrate clinical benefit despite target engagement

Competition: Approved agents may dominate market

Dosing: May require higher doses for efficacy

Commercial: Market access challenges

Biomarker Science and Validation

Amyloid Biomarkers

The trial incorporates comprehensive biomarker assessment:

Amyloid PET Imaging:

Uses standard tracers (Pittsburgh compound-B, florbetapir)
Measures cortical amyloid burden in Centiloids
Tracks changes over treatment period
Required for patient selection and response

CSF Biomarkers:

Aβ42/40 ratio (decreased in AD)
Total tau and phosphorylated tau
Oligomer-specific assays (emerging)
Optional lumbar puncture component

Blood-Based Biomarkers:

Plasma Aβ42/40 ratio
p-tau181 and p-tau217
GFAP (astrocytic activation)

-NfL (neurodegeneration)

Tau Biomarkers

Tau pathology assessment includes:

Imaging:

Tau PET with approved tracers
Braak staging by imaging
Correlates with clinical severity

Fluid:

CSF p-tau181
Blood p-tau217 (emerging)
Tracks disease progression

Neuroinflammatory Biomarkers

Assessment of neuroinflammation:

Microglial Markers:

CSF sTREM2
Plasma GFAP
PET with TSPO tracers (research)

Inflammatory Cytokines:

IL-6, IL-1β, TNF-α
Longitudinal tracking

Biomarker Integration

Multi-modal biomarker approach:

| Biomarker | Purpose | Measurement |
|----------|--------|-------------|
| Amyloid PET | Diagnosis confirmation | Centiloids |
| Tau PET | Disease staging | SUVR |
| CSF Aβ42 | Target engagement | Concentration |
| p-tau217 | Disease progression | Plasma |
|NfL | Neurodegeneration | Plasma/CSF |

Patient Experience

Clinical Trial Participation

Patients considering participation should understand:

Potential Benefits:

Access to investigational therapy
Comprehensive medical monitoring
Contribution to AD research

Risks and Burdens:

Unknown safety profile
Regular infusions required
Significant time commitment
MRI monitoring

Trial Logistics

Visit Schedule:

Screening: 4 weeks
Treatment: Every 4 weeks for 12+ months
Follow-up: 3-6 months post-treatment

Required Procedures:

MRI (screening, periodic)
Cognitive testing (every 3-6 months)
Lumbar puncture (optional)
Blood draws (regular)

Healthcare System Impact

Health Economics

Successful development would impact healthcare:

Cost Considerations:

Development investment: $200-500M
Manufacturing costs: Significant
Pricing: To be determined

Potential Benefits:

Reduced institutional care costs
Delayed nursing home placement
Caregiver burden reduction

Access and Distribution

Following potential approval:

US Launch:

Specialty pharmacy distribution
Infusion center network
Patient assistance programs

Global Expansion:

EU MAA submission
Japan PMDA
International registrations

Regulatory Strategy and Global Development

FDA Engagement

ProMis Neurosciences has engaged proactively with regulators:

Pre-IND Meeting:

FDA Type B meeting completed
Trial design feedback incorporated
CMC requirements clarified

Fast Track Designation:

Granted based on unmet need
Enhances regulatory interactions
Accelerates development timeline

Breakthrough Therapy:

Potential based on mechanism
May enable accelerated approval
Requires efficacy demonstration

Global Development Strategy

Multi-regional development approach:

United States:

Primary clinical development
FDA regulation
US patient population priority

European Union:

EMA scientific advice
EU clinical sites
MAA submission post- approvals

Asia-Pacific:

Japan PMDA consultations
Singapore and Australia sites
Accelerated access pathway

Development Partnerships

Strategic collaborations support development:

Pharmaceutical Partnerships:

Commercialization agreements
Manufacturing partnerships
Co-development opportunities

Academic Collaborations:

Clinical trial sites
Biomarker development
Basic research partnerships

Patient Advocacy:

Disease awareness
Trial recruitment support
Post-approval access

Market Analysis and Commercial Considerations

Market Opportunity

The AD therapeutics market represents substantial opportunity:

Disease Prevalence:

55+ million people with AD worldwide
6+ million in US alone
Growing with aging populations

Current Treatments:

Symptomatic therapies (modest benefit)
Two anti-amyloid antibodies approved
Significant unmet need remains

Market Dynamics:

Increasing diagnosis rates
Improved reimbursement
Healthcare system investment

Competitive Landscape

PMN310 enters a competitive market:

Approved Agents:

Lecanemab (Leqembi): $21,000/year
Donanemab (Kisunla): $32,000/year

Pipeline Competition:

Multiple anti-amyloid antibodies
Alternative mechanisms
Small molecules

Commercial Strategy

If approved, commercial considerations include:

Pricing:

Value-based pricing
Competitor benchmarks
Reimbursement negotiations

Distribution:

Specialty pharmacy
Infusion center network
Patient assistance programs

Marketing:

Physician education
Patient awareness
Payer engagement

Clinical Pharmacology and Pharmacokinetics

Absorption

PMN310 is administered intravenously:

Bioavailability:

100% by IV infusion
Dose-proportional exposure
Steady-state achieved by Week 12

Distribution:

Limited extravascular distribution
CSF penetration demonstrated
Brain exposure sufficient for target engagement

Metabolism

As a monoclonal antibody:

Catabolic pathways:

Proteolytic degradation
No hepatic metabolism
Amino acid recycling

Half-life:

Approximately 21-28 days
Allows monthly dosing
Accumulation with repeat dosing

Elimination

Primary elimination:

IgG catabolism
No renal or hepatic clearance
FcRn-mediated recycling

Drug Interactions

Immunomodulatory potential:

Limited interaction risk
No CYP-mediated metabolism
Minimal drug-drug interaction potential

Population Pharmacokinetics

Special populations:

Geriatric patients: No adjustment needed
Hepatic impairment: Not studied
Renal impairment: No adjustment expected

Pharmacodynamic Relationships

Exposure-Response

Efficacy:
-Amyloid PET reduction correlates with exposure

Clinical benefit at higher exposures
Dose-response characterization ongoing

Safety:

ARIA incidence appears exposure-dependent
Higher doses: increased ARIA risk
Risk-benefit optimization in progress

Biomarker Engagement

Target engagement biomarkers:

Plasma Aβ42/40 ratio changes
CSF oligomer reduction (research assay)
Amyloid PET changes

Disease progression biomarkers:

Plasma p-tau217
Neurofilament light chain
Brain volume changes

Manufacturing and Quality Control

Drug Substance

Production:

CHO cell expression system
Purified by protein A chromatography
Formulated for intravenous delivery

Quality Control:

Identity testing
Purity assessment
Potency assays
Stability monitoring

Drug Product

Formulation:

Lyophilized for stability
Reconstituted before infusion
100 mg/mL concentration

Storage:

2-8°C refrigerator
Protect from light
24-month shelf life

Supply Chain

Manufacturing:

Scale-up completed for Phase 2/3
Commercial manufacturing validation
Global supply network

Distribution:

Specialty pharmacy network
Cold chain logistics
Temperature monitoring

Summary

PMN310 represents a differentiated approach to Alzheimer's disease therapy through selective targeting of amyloid-beta oligomers. The ongoing PRECISE-AD trial (NCT06750432) will test whether oligomer targeting translates to clinical efficacy.

Key Points:

Novel mechanism targeting toxic oligomers

Phase 1/2 clinical evaluation ongoing

Potential ARIA advantage vs. plaque-targeting antibodies

Development timeline: 5+ years to potential approval

Outlook:
The success of PMN310 will depend on:

Demonstrating acceptable safety profile
Achieving target engagement
Showing preliminary efficacy signals
Validating oligomer hypothesis in humans

References

[ProMis Neurosciences Corporate Overview (2024)](https://www.promisneurosciences.com)

[PRECISE-AD Study Details (2024)](https://clinicaltrials.gov/study/NCT06750432)

[Amyloid Oligomer Hypothesis in AD, Nature Reviews Neuroscience (2023)](https://pubmed.ncbi.nlm.nih.gov/37890123/)

[Anti-Amyloid Antibody ARIA Safety, Neurobiology of Aging (2024)](https://doi.org/10.1016/j.neurobiolaging.2024.01.015)

[Lecanemab in Early Alzheimer's Disease, NEJM (2023)](https://doi.org/10.1056/NEJMoa2212948)

[Donanemab in Early Alzheimer's Disease, NEJM (2024)](https://doi.org/10.1056/NEJMoa2304130)

[Amyloid-Beta Oligomer-Selective Antibodies, Brain (2024)](https://doi.org/10.1093/brain/awae072)

[Neuroinflammation in Alzheimer's Disease, Nature Reviews Neurology (2024)](https://doi.org/10.1038/s41582-024-00848-z)

Pathway Diagram

Mermaid diagram (expand to render)

slug	clinical-trials-nct06750432-pmn310-anti-amyloid
kg_node_id	None
entity_type	clinical
origin_type	v1_polymorphic_backfill
source_table	wiki_pages
wiki_page_id	wp-d84eb6401aea
__merged_from	{'merged_at': '2026-05-13', 'unprefixed_id': 'clinical-trials-nct06750432-pmn310-anti-amyloid'}
_schema_version	1

📗 Cite This Artifact

PMN310 Anti-Amyloid for AD (NCT06750432)

Amyloid Oligomer Hypothesis

Historical Context

Amyloid Oligomer Hypothesis

Historical Context

Evidence for Oligomer Toxicity

Structural Basis for Selective Targeting

Mechanism of Action

Antibody Binding Specificity

Target Engagement Mechanisms

Comparison to Other Anti-Amyloid Antibodies

ProMis Neurosciences Platform

Discovery Approach

Pipeline Beyond PMN310

Clinical Trial Design

NCT06750432 (PRECISE-AD Study)

Trial Phases

Patient Population

Endpoints

Biomarker Strategy

Development Rationale

Why Target Oligomers

Clinical Context

Competition and Pipeline Context

Anti-Amyloid Antibody Landscape

Oligomer-Targeting Competitors

Market Opportunity

Amyloid-Beta Biology and Pathogenesis

APP Processing and Aβ Generation

Aβ Aggregation and Oligomer Formation

Structural Biology of PMN310

Epitope Recognition

Comparison of Anti-Aβ Antibody Approaches

Clinical Development History

ProMis Neurosciences Company Background

Lessons from Previous Anti-Amyloid Failures

Safety Profile and ARIA

Amyloid-Related Imaging Abnormalities (ARIA)

PMN310 Safety Considerations

Pharmacokinetics and Pharmacodynamics

Pharmacokinetic Profile

Pharmacodynamic Markers

Regulatory Considerations

Accelerated Approval Pathway

Development Challenges

Future Directions

Potential Development Path

Long-term Vision

Clinical Development Program

Phase 1/2 Trial Design

Safety Profile Considerations

Comparison with Approved Therapies

Regulatory Pathway

Breakthrough Therapy Designation

Future Development Plans

Cross-References

Clinical Development History and Timeline

Discovery Phase (2019-2021)

Preclinical Development (2021-2022)

Clinical Development (2023-2026)

Timeline Projections

Competitive Positioning

Comparative Analysis

Potential Advantages

Development Risks

Biomarker Science and Validation

Amyloid Biomarkers

Tau Biomarkers

Neuroinflammatory Biomarkers

Biomarker Integration

Patient Experience

Clinical Trial Participation

Trial Logistics

Healthcare System Impact

Health Economics

Access and Distribution

Regulatory Strategy and Global Development

FDA Engagement

Global Development Strategy